# Cardioprotective and Metabolic Effects of Metformin in Patients With Heart Failure and Diabetes

> **NCT01690091** · PHASE2,PHASE3 · COMPLETED · sponsor: **Institute for Clinical and Experimental Medicine** · enrollment: 40 (actual)

## Conditions studied

- Insulin Resistance
- Chronic Heart Failure

## Interventions

- **DRUG:** Metformini hydrochloridum (Siofor 1000 tbl, Berlin)
- **DRUG:** placebo

## Key facts

- **NCT ID:** NCT01690091
- **Lead sponsor:** Institute for Clinical and Experimental Medicine
- **Sponsor class:** OTHER_GOV
- **Phase:** PHASE2,PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2012-11
- **Primary completion:** 2016-05
- **Final completion:** 2016-12
- **Target enrollment:** 40 (ACTUAL)
- **Last updated:** 2018-03-29


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01690091

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01690091, "Cardioprotective and Metabolic Effects of Metformin in Patients With Heart Failure and Diabetes". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT01690091. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*